Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Vipivotide tetraxetan (PSMA-617) is a high potent inhibitor of prostate-specific membrane antigen (PSMA)(Ki of 0.37 nM).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 193.00 | |
2 mg | In stock | $ 287.00 | |
5 mg | In stock | $ 483.00 | |
10 mg | In stock | $ 691.00 | |
25 mg | In stock | $ 1,080.00 | |
50 mg | In stock | $ 1,490.00 | |
100 mg | In stock | $ 1,960.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 1,190.00 |
Description | Vipivotide tetraxetan (PSMA-617) is a high potent inhibitor of prostate-specific membrane antigen (PSMA)(Ki of 0.37 nM). |
Targets&IC50 | PSMA:0.37 nM(Ki) |
In vitro | The chemically modified PSMA inhibitor PSMA-617 demonstrated high radiolytic stability for at least 72 h. A high inhibition potency (equilibrium dissociation constant [K(i)] = 2.34 2.94 nM on LNCaP; K(i) = 0.37 0.21 nM enzymatically determined) and highly efficient internalization into LNCaP cells were demonstrated. |
In vivo | The small-animal PET measurements showed high tumor-to-background contrasts as early as 1 h after injection of Vipivotide tetraxetan.Organ distribution revealed specific uptake in LNCaP tumors and in the kidneys 1 h after injection of Vipivotide tetraxetan[1]. |
Synonyms | PSMA-617 |
Molecular Weight | 1042.14 |
Formula | C49H71N9O16 |
CAS No. | 1702967-37-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (95.96 mM), Sonication is recommended.
H2O: 100 mg/mL (95.96 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Vipivotide tetraxetan 1702967-37-0 Others Inhibitor PSMA-617 PSMA 617 Drug-Linker Conjugates for ADC inhibit PSMA617 inhibitor